Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma

NCT01199718 is registered in ClinicalTrials.gov with Cylene Pharmaceuticals as lead sponsor.

NCT NCT01199718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01199718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Cylene Pharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
September 30, 2010
Completion date
September 30, 2011
Enrollment
22 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma